文献速递艾滋病与性传播感染病毒性肝炎

HIV-HCV共感染者DAA治疗后肝纤维化与免疫特征的长期演变

Long-term evolution in liver fibrosis and immune profile after direct-acting antivirals therapy in hepatitis C virus-human immunodeficiency virus co-infected patients.
PubMed 文献 · Clin Microbiol Infect · 2021-08-28

该回顾性单中心队列纳入410例2013年6月至2018年6月接受直接抗病毒药物(DAA)治疗的HIV-HCV共感染者,分析随访中肝纤维化与免疫指标变化。结果显示肝纤维化逐步改善,CD8计数下降且CD4/CD8比值长期上升。

要点

  • DAA治疗后肝纤维化逐步改善,基线纤维化越重改善越明显。
  • 瞬态弹性成像值较基线下降≥30%的比例随随访延长而增加。
  • CD8计数在48个月时显著下降,CD4/CD8比值在24个月后逐步上升。

核心结论

  • HIV-HCV共感染者接受DAA治疗与肝纤维化显著逐步改善及免疫系统恢复相关,长期随访中CD4/CD8比值上升。

研究设计与样本

  • 回顾性单中心队列研究,纳入2013年6月至2018年6月接受DAA治疗的HIV-HCV共感染者410例。

主要发现

  • 基于瞬态弹性成像值较基线下降的肝纤维化改善见于43%(131/302)的患者,基于生物学评分(APRI:124/398;FIB-4:104/398)的改善见于31%的患者(p < 0.0001),基线纤维化晚期者改善更常见(83/144)。
  • DAA治疗后6个月观察到最大降幅(-0.23;95% CI -0.29至-0.18),瞬态弹性成像值较基线下降至少30%的患者比例在6个月为32%、24个月为51%、48个月为55%。
  • CD8计数在48个月时显著下降(-62.38;95% CI -106.77至-17.99;p 0.0001),CD4/CD8比值在随访24个月后逐步上升,48个月时增加+0.07(95% CI 0.03-0.10,p 0.0001)。

临床怎么用

  • 对HIV-HCV共感染者DAA治疗后应长期监测肝纤维化与免疫指标,关注纤维化改善及CD4/CD8比值变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Hepatitis C virus (HCV) therapy with direct-acting antivirals (DAA) achieves high rates of sustained virological response in people living with human immunodeficiency virus (HIV) (PLWH). Information on its long-term clinical impact is scarce. The aim of this study was to analyse liver fibrosis and immune response evolution after DAA treatment. METHODS: Retrospective, single centre cohort study of HIV-HCV co-infected patients treated with DAA between June 2013 and June 2018. We analysed the changes during follow up in liver fibrosis (assessed by transient elastography (TE), aspartate aminotransferase to platelet ratio index (APRI) and FIB-4 scores) and immunity (CD4 and CD8 cells counts and CD4/CD8 ratio). RESULTS: We included 410 patients; 75% (308/407) men with a mean age of 50 years (SD 8); 78% (318/410) had long chronic HCV infection (median 21 years, interquartile range (IQR) 6-27 years) and 27% (107/393) had liver cirrhosis. Liver fibrosis improvement based on the decrease in TE value compared with the baseline occurred in 43% (131/302) of patients and 31% of patients based on biological scores (APRI: 124/398; FIB-4: 104/398) (p < 0.0001), being more frequent in those with advanced baseline fibrosis (83/144). The higher decrease was observed at 6 months after DAA therapy (-0.23; 95% CI -0.29 to -0.18), but a continuum in fibrosis regression of at least 30% from baseline value of TE was observed along the follow up (32% of patients at month 6, 51% at month 24 and 55% at month 48). Regarding the immunological profile, there was a significant decrease in CD8 counts at month 48 (-62.38; 95% CI -106.77 to -17.99; p 0.0001) and a progressive rise in the CD4/CD8 ratio after 24 months of follow up reaching an increment of +0.07 (95% CI 0.03-0.10, p 0.0001) at month 48. CONCLUSIONS: HCV treatment with DAA in PLWH is associated with significant progressive improvement in liver fibrosis and recovery of the immune system with an increase in the CD4/CD8 ratio in long-term follow up.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Laguno M, Martínez-Rebollar M, Casanova M, et al. Long-term evolution in liver fibrosis and immune profile after direct-acting antivirals therapy in hepatitis C virus-human immunodeficiency virus co-infected patients. Clin Microbiol Infect. 2021. PMID: 34464735. doi:10.1016/j.cmi.2021.08.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。